Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Cash from Operations (2016 - 2025)

Ironwood Pharmaceuticals (IRWD) has disclosed Cash from Operations for 16 consecutive years, with 74575000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations rose 390.17% to 74575000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 127044000.0 through Dec 2025, up 22.69% year-over-year, with the annual reading at 127044000.0 for FY2025, 22.69% up from the prior year.
  • Cash from Operations hit 74575000.0 in Q4 2025 for Ironwood Pharmaceuticals, up from 47583000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 80171000.0 in Q1 2023 to a low of 15068000.0 in Q2 2025.
  • Historically, Cash from Operations has averaged 47483900.0 across 5 years, with a median of 48075500.0 in 2021.
  • Biggest YoY gain for Cash from Operations was 390.17% in 2025; the steepest drop was 145.03% in 2025.
  • Year by year, Cash from Operations stood at 64568000.0 in 2021, then rose by 22.63% to 79182000.0 in 2022, then plummeted by 54.74% to 35834000.0 in 2023, then tumbled by 57.54% to 15214000.0 in 2024, then surged by 390.17% to 74575000.0 in 2025.
  • Business Quant data shows Cash from Operations for IRWD at 74575000.0 in Q4 2025, 47583000.0 in Q3 2025, and 15068000.0 in Q2 2025.